PURPOSE: The aim of this study was to evaluate the association of PON1 genetic variants with the susceptibility to coronary artery disease (CAD) and with the clinical endpoints in aspirin and clopidogrel (dual antiplatelet therapy)-treated Han Chinese patients with CAD after percutaneous coronary intervention (PCI). METHODS: A total of 538 Han Chinese patients undergoing PCI and receiving dual-antiplatelet therapy were sequentially recruited to the study and followed for up to 1 year. Healthy controls (n = 539) were enrolled during the same period. All study participants were genotyped for five genetic variants in PON1 and the cytochrome P450 2C19*2 mutation (CYP2C19*2). The effect of genetic variants on disease risk and clinical outcome of major adverse cardiac events (MACE) within 1 year or bleeding within 6 months was assessed. RESULTS: CYP2C19*2 was associated with a higher risk of MACE (adjusted P = 0.0098), but a lower risk of bleeding events (adjusted P = 0.0016). The PON1 Q192R polymorphism was significantly associated with a lower risk of bleeding events [odds ratio (OR) 0.61, 95% confidence interval (CI) 0.43-0.87, adjusted P = 0.0066). The haplotype bearing the PON1 -126C allele was associated with a higher risk to CAD (OR 1.48, 95% CI 1.04-2.09, P = 0.029) and a higher risk of bleeding events (OR 1.68, 95% CI 1.10-2.56, P = 0.017) compared to the most frequent haplotype. The transcription activity of haplotype p-162A-126C-108C in the PON1 promoter was 2.6-fold higher than that of the most frequent haplotype (p-162G-126G-108T). CONCLUSIONS: Based on these results, we suggest that the haplotype-bearing PON1 -126C allele contributes to the disease risk and the risk of bleeding events in dual antiplatelet-treated CAD patients after PCI.
PURPOSE: The aim of this study was to evaluate the association of PON1 genetic variants with the susceptibility to coronary artery disease (CAD) and with the clinical endpoints in aspirin and clopidogrel (dual antiplatelet therapy)-treated Han Chinese patients with CAD after percutaneous coronary intervention (PCI). METHODS: A total of 538 Han Chinese patients undergoing PCI and receiving dual-antiplatelet therapy were sequentially recruited to the study and followed for up to 1 year. Healthy controls (n = 539) were enrolled during the same period. All study participants were genotyped for five genetic variants in PON1 and the cytochrome P450 2C19*2 mutation (CYP2C19*2). The effect of genetic variants on disease risk and clinical outcome of major adverse cardiac events (MACE) within 1 year or bleeding within 6 months was assessed. RESULTS:CYP2C19*2 was associated with a higher risk of MACE (adjusted P = 0.0098), but a lower risk of bleeding events (adjusted P = 0.0016). The PON1Q192R polymorphism was significantly associated with a lower risk of bleeding events [odds ratio (OR) 0.61, 95% confidence interval (CI) 0.43-0.87, adjusted P = 0.0066). The haplotype bearing the PON1 -126C allele was associated with a higher risk to CAD (OR 1.48, 95% CI 1.04-2.09, P = 0.029) and a higher risk of bleeding events (OR 1.68, 95% CI 1.10-2.56, P = 0.017) compared to the most frequent haplotype. The transcription activity of haplotype p-162A-126C-108C in the PON1 promoter was 2.6-fold higher than that of the most frequent haplotype (p-162G-126G-108T). CONCLUSIONS: Based on these results, we suggest that the haplotype-bearing PON1 -126C allele contributes to the disease risk and the risk of bleeding events in dual antiplatelet-treated CAD patients after PCI.
Authors: Luis M Moura; Susana Faria; Miguel Brito; Fausto J Pinto; Steen D Kristensen; Isabel M Barros; Nalini Rajamannan; Francisco Rocha-Gonçalves Journal: Am J Cardiovasc Dis Date: 2012-05-15
Authors: Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert Journal: Nat Med Date: 2010-12-19 Impact factor: 53.440
Authors: V H Brophy; R L Jampsa; J B Clendenning; L A McKinstry; G P Jarvik; C E Furlong Journal: Am J Hum Genet Date: 2001-05-02 Impact factor: 11.025
Authors: Jakub J Regieli; J Wouter Jukema; Pieter A Doevendans; Aeilko H Zwinderman; John J Kastelein; Diederick E Grobbee; Yolanda van der Graaf Journal: J Am Coll Cardiol Date: 2009-09-29 Impact factor: 24.094
Authors: Vincent Dunet; Juan Ruiz; Gilles Allenbach; Paola Izzo; Richard W James; John O Prior Journal: EJNMMI Res Date: 2011-11-18 Impact factor: 3.138
Authors: Rakesh S Birjmohun; Menno Vergeer; Erik S G Stroes; Manjinder S Sandhu; Sally L Ricketts; Michael W Tanck; Nicholas J Wareham; J Wouter Jukema; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt Journal: PLoS One Date: 2009-08-27 Impact factor: 3.240
Authors: Alicja E Grzegorzewska; Adrianna Mostowska; Wojciech Warchoł; Paweł P Jagodziński Journal: BMC Infect Dis Date: 2021-08-26 Impact factor: 3.090
Authors: Yazmín Hernández-Díaz; Carlos Alfonso Tovilla-Zárate; Isela Esther Juárez-Rojop; Thelma Beatriz González-Castro; Candelario Rodríguez-Pérez; María Lilia López-Narváez; José Manuel Rodríguez-Pérez; José Francisco Cámara-Álvarez Journal: Medicine (Baltimore) Date: 2016-11 Impact factor: 1.889
Authors: Ericha G Franey; Donna Kritz-Silverstein; Erin L Richard; John E Alcaraz; Caroline M Nievergelt; Richard A Shaffer; Vibha Bhatnagar Journal: J Aging Res Date: 2020-03-21